Showing results (61-70 of 84) with videos related to
Sort By:
Pageof 9
Cell|June 17, 2008
BAP31 interacts with Sec61 translocons and promotes retrotranslocation of CFTRDeltaF508 via the derlin-1 complexBing Wang, Hannah Heath-Engel, Donglei Zhang, et al.BMC Cancer|August 2, 2015
Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces BimMai Nguyen, Regina Cencic, Franziska Ertel, et al.FEBS Letters|October 11, 2005
BH3-ligand regulates access of MCL-1 to its E3 ligaseMatthew R Warr, Stephane Acoca, Zhiqian Liu, et al.Oncotarget|August 29, 2015
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2Andrew R Lavik, Fei Zhong, Ming-Jin Chang, et al.Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptorYi-Ping Rong, Geert Bultynck, Ademuyiwa S Aromolaran, et al.The Journal of Biological Chemistry|March 26, 2003
Solution structure of human BCL-w: modulation of ligand binding by the C-terminal helixAlexei Yu Denisov, Murthy S R Madiraju, Gang Chen, et al.Plos One|August 13, 2013
Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagyWei Michael Liu, Ping Huang, Niladri Kar, et al.Blood|January 4, 2011
Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interactionFei Zhong, Michael W Harr, Geert Bultynck, et al.Journal of Leukemia (Los Angeles, Calif.)|May 19, 2015
Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL MicroenvironmentAshley E Rosko, Karen S McColl, Fei Zhong, et al.Anti-Cancer Drugs|June 8, 2018
DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapyCynthia Bernier, Ahmed Soliman, Michel Gravel, et al.Pageof 9